Global dual incretin agonists market set to reach $85.80bn by 2034

11 articles · Updated · Fortune Business Insights · May 7

Fortune Business Insights said the market was worth $36.51bn in 2025 and is forecast at $47.23bn in 2026, with 7.75% annual growth through 2034.
Demand is being driven by obesity and type 2 diabetes, as dual-action therapies gain traction for combining blood-sugar control with weight reduction and broader cardiometabolic benefits.
North America led in 2025, tirzepatide held the largest drug segment, and growth is supported by pipeline expansion, though high costs, reimbursement limits and manufacturing capacity remain constraints.

Will next-gen oral pills and novel science finally break the cost and access barriers of today's blockbuster shots?

With Medicare negotiating prices, can pharma giants sustain blockbuster profits while making these miracle drugs affordable for all?

As 'super-zepbounds' promise greater weight loss, are we solving obesity or creating lifelong drug dependency?